amifostine anhydrous has been researched along with Female Genital Neoplasms in 6 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mell, LK | 1 |
| Movsas, B | 1 |
| Gold, MA | 1 |
| Walker, JL | 1 |
| Berek, JS | 1 |
| Hallum, AV | 1 |
| Garcia, DJ | 1 |
| Alberts, DS | 2 |
| Kouloulias, VE | 1 |
| Kouvaris, JR | 1 |
| Pissakas, G | 1 |
| Mallas, E | 1 |
| Antypas, C | 1 |
| Kokakis, JD | 1 |
| Matsopoulos, G | 1 |
| Michopoulos, S | 1 |
| Mystakidou, K | 1 |
| Vlahos, LJ | 1 |
| Brady, LW | 1 |
| Phillips, TL | 1 |
| Wasserman, TH | 1 |
| Safra, T | 1 |
| Jeffers, S | 1 |
| Sorich, J | 1 |
| Muggia, FM | 1 |
3 reviews available for amifostine anhydrous and Female Genital Neoplasms
| Article | Year |
|---|---|
Pharmacologic normal tissue protection in clinical radiation oncology: focus on amifostine.
Topics: Amifostine; Female; Genital Neoplasms, Female; Head and Neck Neoplasms; Humans; Neoplasms; Radiation | 2008 |
The potential for radiation sensitizers and radiation protectors combined with radiation therapy in gynecologic cancer.
Topics: Amifostine; Animals; Clinical Trials as Topic; Drug Evaluation, Preclinical; Female; Genital Neoplas | 1981 |
Future directions in gynecologic cancer.
Topics: Amifostine; Antineoplastic Agents; Clinical Trials as Topic; Cytoprotection; Female; Genital Neoplas | 1999 |
3 trials available for amifostine anhydrous and Female Genital Neoplasms
| Article | Year |
|---|---|
Amifostine pretreatment for protection against topotecan-induced hematologic toxicity: results of a multicenter phase III trial in patients with advanced gynecologic malignancies.
Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Female; Genital Neoplasms, Female; Humans; Middle Ag | 2003 |
Phase II multicenter randomized study of amifostine for prevention of acute radiation rectal toxicity: topical intrarectal versus subcutaneous application.
Topics: Administration, Rectal; Amifostine; Female; Genital Neoplasms, Female; Humans; Injections, Subcutane | 2005 |
The potential for radiation sensitizers and radiation protectors combined with radiation therapy in gynecologic cancer.
Topics: Amifostine; Animals; Clinical Trials as Topic; Drug Evaluation, Preclinical; Female; Genital Neoplas | 1981 |
1 other study available for amifostine anhydrous and Female Genital Neoplasms
| Article | Year |
|---|---|
Gemcitabine plus cisplatin combination given with amifostine (GAP) to heavily pretreated patients with gynecologic and peritoneal cancers: tolerance and activity in ovarian cancer.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; D | 1998 |